Finanzen von Surmodics Inc (SRDX)SRDXSurmodics Inc

Surmodics Inc (SRDX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medical Device, accounting for 75.1% of total sales, equivalent to $22.21M. Another important revenue stream is In Vitro Diagnostics. Understanding this composition is critical for investors evaluating how SRDX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Surmodics Inc maintains a gross margin of 67.92%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.20%, while the net margin is -17.99%. These profitability ratios, combined with a Return on Equity (ROE) of -15.36%, provide a clear picture of how effectively SRDX converts its operational activities into shareholder value.

In the context of the broader market, SRDX competes directly with industry leaders such as OFIX and BVS. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SRDX's gross margin of 67.92% stands against OFIX's 70.97% and BVS's 68.29%. Such benchmarking helps identify whether Surmodics Inc is trading at a premium or discount relative to its financial performance.